Steg Philippe Gabriel, Dabbous Omar H, Feldman Laurent J, Cohen-Solal Alain, Aumont Marie-Claude, López-Sendón José, Budaj Andrzej, Goldberg Robert J, Klein Werner, Anderson Frederick A
Centre Hospitalier Universitaire Bichat-Beaujon, Assistance Publique-Hôpitaux de Paris, France.
Circulation. 2004 Feb 3;109(4):494-9. doi: 10.1161/01.CIR.0000109691.16944.DA. Epub 2004 Jan 26.
Few data are available on the impact of heart failure (HF) across all types of acute coronary syndromes (ACS).
The Global Registry of Acute Coronary Events (GRACE) is a prospective study of patients hospitalized with ACS. Data from 16 166 patients were analyzed: 13 707 patients without prior HF or cardiogenic shock at presentation were identified. Of these, 1778 (13%) had an admission diagnosis of HF (Killip class II or III). HF on admission was associated with a marked increase in mortality rates during hospitalization (12.0% versus 2.9% [with versus without HF], P<0.0001) and at 6 months after discharge (8.5% versus 2.8%, P<0.0001). Of note, HF increased mortality rates in patients with unstable angina (defined as ACS with normal biochemical markers of necrosis; mortality rates: 6.7% with versus 1.6% without HF at admission, P<0.0001). By logistic regression analysis, admission HF was an independent predictor of hospital death (odds ratio, 2.2; P<0.0001). Admission HF was associated with longer hospital stay and higher readmission rates. Patients with HF had lower rates of catheterization and percutaneous cardiac intervention, and fewer received beta-blockers and statins. Hospital development of HF (versus HF on presentation) was associated with an even higher in-hospital mortality rate (17.8% versus 12.0%, P<0.0001). In patients with HF, in-hospital revascularization was associated with lower 6-month death rates (14.0% versus 23.7%, P<0.0001; adjusted hazard ratio, 0.5; 95% CI, 0.37 to 0.68, P<0.0001).
In this observational registry, heart failure was associated with reduced hospital and 6-month survival across all ACS subsets, including patients with normal markers of necrosis. More aggressive treatment of these patients may be warranted to improve prognosis.
关于心力衰竭(HF)对所有类型急性冠状动脉综合征(ACS)的影响,现有数据较少。
全球急性冠状动脉事件注册研究(GRACE)是一项针对因ACS住院患者的前瞻性研究。分析了16166例患者的数据:确定了13707例就诊时无既往HF或心源性休克的患者。其中,1778例(13%)入院诊断为HF(Killip分级II或III级)。入院时HF与住院期间死亡率显著增加相关(12.0%对2.9%[有HF与无HF],P<0.0001)以及出院后6个月死亡率(8.5%对2.8%,P<0.0001)。值得注意的是,HF增加了不稳定型心绞痛患者的死亡率(定义为坏死生化标志物正常的ACS;死亡率:入院时有HF为6.7%,无HF为1.6%,P<0.0001)。通过逻辑回归分析,入院时HF是医院死亡的独立预测因素(比值比,2.2;P<0.0001)。入院时HF与住院时间延长和再入院率升高相关。HF患者的导管插入术和经皮心脏介入治疗率较低,接受β受体阻滞剂和他汀类药物治疗的患者较少。医院内发生HF(与就诊时即有HF相比)与更高的住院死亡率相关(17.8%对12.0%,P<0.0001)。在HF患者中,住院期间血管重建与6个月较低的死亡率相关(14.0%对23.7%,P<0.0001;校正风险比,0.5;95%CI,0.37至0.68,P<0.0001)。
在这项观察性注册研究中,心力衰竭与所有ACS亚组患者(包括坏死标志物正常的患者)住院期间及6个月生存率降低相关。可能需要对这些患者进行更积极的治疗以改善预后。